Katrina Gwinn
YOU?
Author Swipe
View article: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease
Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease Open
A fixed one-sided significance level of 5% is commonly used to interpret the statistical significance of randomized clinical trial (RCT) outcomes. While it is necessary to reduce the false positive rate, the threshold used could be chosen …
View article: Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study Open
Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are…
View article: Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s Disease
Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s Disease Open
Introduction. A growing literature has developed on identifying outcomes that matter to patients. This study demonstrates an approach involving patient and regulatory perspectives to identify outcomes that are meaningful in the context of …
View article: Finding useful biomarkers for Parkinson’s disease
Finding useful biomarkers for Parkinson’s disease Open
The recent advent of an “ecosystem” of shared biosample biorepositories and data sets will aid efforts to define biomarkers for Parkinson’s disease.
View article: Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features Open
Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha‐synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha‐synuclein differentiate…
View article: <i>COL4A2</i> is associated with lacunar ischemic stroke and deep ICH
<i>COL4A2</i> is associated with lacunar ischemic stroke and deep ICH Open
These results provide evidence of shared genetic determinants and suggest common pathophysiologic mechanisms of distinct ischemic and hemorrhagic cerebral SVD stroke phenotypes, offering new insights into the causal mechanisms of cerebral …
View article: Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program
Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program Open
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Strok…
View article: The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort Open
Background Identifying PD‐specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity o…